Thermo Fisher Scientific Inc. is investing $180 million to expand capacity for viral vector development and manufacturing services with a new commercial manufacturing site in Plainville, MA. The project will more than double the company’s commercial viral vector capacity to support increasing demand for the development and manufacture of gene therapies and vaccines. Construction of the new 290,000-sq.-ft. facility is expected to be completed in 2022. The project will add more than 200 j...